4 research outputs found

    Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients

    Get PDF
    BACKGROUND: /Aim. KIT (KIT proto-oncogene receptor tyrosine kinase) and PDGFRA (platelet-derived growth factor receptor alpha) gene mutations represent major molecular forces inside the gastrointestinal stromal tumors (GIST). Aim of this study was to evaluate these mutations in the patients who underwent surgical resection of gastric GIST, but without imatinib mesylate treatment. Methods. Retrospective clinical study included patients who were operated on due to gastric GIST from November 2000 till November 2016. A molecular analysis of paraffin embedded tumor tissue was performed, and the patients with the presence of KIT and PDGFRA mutations were further evaluated, with regard to the pathological tumor stage, disease recurrence and overall survival. Results. Out of 45 patients in total, 43 patients had KIT and PDGFRA mutations, and 2 patients were classified as the wild type GIST. After curative resection, 11 patients were classified as a low risk GIST, 8 as an intermediate risk and 26 as a high risk GIST. The KIT mutations were present in 37 patients, most commonly as deletion in exon 11. The PDGFRA mutations were present in 6 patients. The presence of KIT mutation had a strong statistical correlation with the mitotic index (p = 0.021). After the ten-year follow-up, all patients with the PDGFRA mutations were alive, while those with the KIT mutations had a survival rate of 71% (p = 0.31). Conclusion. The presence of KIT exon 11 deletion in the patients with primarily resected gastric GIST is associated with the higher mitotic index and worse overall survival than those present with the PDGFRA mutations. This results suggest prognostic significance towards more aggressive behaviors

    Significance of KIT and PDGFRA gene mutation in evaluation of surgically treated gastric gastrointestinal stromal tumor patients

    Get PDF
    Cilj: Ispitivanje genetskih mutacija na KIT i PDGFRA genima, prikazivanje njihove učestalosti, vrste mutacija i korelacije ovih specifičnih genskih mutacija sa patohistološkim i imunohistohemijskim karakteristikama tumora. Korelacija genetskih mutacija na KIT i PDGFRA sa kliničkim tokom operisanih bolesnika. Metod: Prospektivna i delimično retrospektivna klinička studija koja je uključila 100 bolesnika operisane zbog GIST-a želuca u period od 2005 do 2016 godine. Načinjena je molekularna analiza na parafinskim kalupima tumorskog tkiva, a kod 45 bolesnika kod kojih su identifikovane KIT i PDGFRA mutacije sprovedena je dalja analiza, sa posebnim osvrtom na patološke karakteristike tumora, recidiv oboljenja i ukupno preživljavanje, te procena uticaja analiziranih genskih mutacija na navedene promene. Rezultati: Od 100 operisanih bolesnika 46% su u grupi visokog rizika od kojih kod 54% nastaju metastaze ili lokalni recidiv. Od ukupno 100 ispitivanih bolesnika, kod 45 bolesnika je dobijen mutacioni status, gde su 37 (82%) bolesnika sa KIT mutacijama, 6 (14%) bolesnika sa PDGFRA mutacije i 2 (4%) bolesnika svrstani u "wild type". Analizom krive preživljavanja kod bolesnika operisanih zbog GIST želuca utvrđena je značajna razlika u javljanju metastaze i smrtnog ishoda u zavisnosti od tipa mutacije(p=0.023). Cox-ovim regresionom analizom je pokazano da bolesnici visokog rizika sa recidivom bolesti koji nisu primali Imatinib imali su 7 puta veću verovatnoću smrtnog ishoda u odnosu na bolesnike lečene Imatinobom Zaključak: Analiza mutacije na KIT i PDGFRA genima ima prognostički i prediktivni značaj kod bolesnika operisanih zbog GIST želuca. Imatinib ima značajnu ulogu u lečenju bolesnika koji su u grupi viskog rizika.Objective: KIT (KIT proto-oncogene receptor tyrosine kinase) and PDGFRA (Platelet derived growth factor receptor alpha) gene mutations represent major molecular forces inside the gastrointestinal stromal tumors (GIST). Aim of this study was to evaluate these mutations in patients who underwent surgical resection of gastric GIST Methods: Retrospective clinical study included 100 patients who were operated due to gastric GIST from 2005 till 2016. Molecular analysis of paraffin embedded tumor tissue was performed, and the 45 patients who had presence of KIT and PDGFRA mutations were further evaluated, with regard to pathological tumor stage, disease recurrence and overall survival. Results: Of the 100 patients who were operated 46% are in the high risk group of which at 54% of the resulting metastasis or local recurrence. From a total of 100 patients, in 45 patients we obtained mutational status, where 37 (82%) of patients had KIT mutations, 6 (14%) patients had PDGFRA mutations and 2 (4%) patients were classified into the “ wild-type”. The analysis of survival curves in patients surgically treated for gastric GIST showed a significant difference in emergence of metastases and death depending on the type of mutation (p = 0.023). Cox's regression analysis shown that patients with a high risk of recurrent disease who were not receiving Imatinib had the 7 times greater probability of fatal outcome compared to patients treated with Imatinib. Conclusion: Analysis of mutations in the genes KIT and PDGFRA has prognostic and predictive significance in patients surgically treated for gastric GIST. Imatinib has an important role in the treatment of patients who are in the group of high risk

    The Utility of Conventional CT, CT Perfusion and Quantitative Diffusion-Weighted Imaging in Predicting the Risk Level of Gastrointestinal Stromal Tumors of the Stomach: A Prospective Comparison of Classical CT Features, CT Perfusion Values, Apparent Diffusion Coefficient and Intravoxel Incoherent Motion-Derived Parameters

    No full text
    Background: The role of advanced functional imaging techniques in prediction of pathological risk categories of gastrointestinal stromal tumors (GIST) is still unknown. The purpose of this study was to evaluate classical CT features, CT-perfusion and magnetic-resonance-diffusion-weighted-imaging (MR-DWI)-related parameters in predicting the metastatic risk of gastric GIST. Patients and methods: Sixty-two patients with histologically proven GIST who underwent CT perfusion and MR-DWI using multiple b-values were prospectively included. Morphological CT characteristics and CT-perfusion parameters of tumor were comparatively analyzed in the high-risk (HR) and low-risk (LR) GIST groups. Apparent diffusion coefficient (ADC) and intravoxel-incoherent-motion (IVIM)-related parameters were also analyzed in 45 and 34 patients, respectively. Results: Binary logistic regression analysis revealed that greater tumor diameter (p < 0.001), cystic structure (p < 0.001), irregular margins (p = 0.007), irregular shape (p < 0.001), disrupted mucosa (p < 0.001) and visible EFDV (p < 0.001), as well as less ADC value (p = 0.001) and shorter time-to-peak (p = 0.006), were significant predictors of HR GIST. Multivariate analysis extracted irregular shape (p = 0.006) and enlarged feeding or draining vessels (EFDV) (p = 0.017) as independent predictors of HR GIST (area under curve (AUC) of predicting model 0.869). Conclusion: Although certain classical CT imaging features remain most valuable, some functional imaging parameters may add the diagnostic value in preoperative prediction of HR gastric GIST
    corecore